李宁，1999年进入同仁堂工作，被分配到同仁堂的中药泛丸制作班组学徒，开始接触西黄丸的制作。经过 拜师学艺与长达25年的实践，李宁已精准、熟练掌握同仁堂西黄丸制作技艺。 在北京市2025年"文化和自然遗产日"非遗宣传展示系列活动启动仪式上，北京市文化和旅游局公布了第五 批北京市级非物质文化遗产代表性传承人名单。北京同仁堂科技发展股份有限公司（以下简称"同仁堂科 技公司"）亦庄分厂中药泛丸高级技师李宁名列其中，被评为北京市级非遗项目"同仁堂西黄丸传统制作技 艺"的代表性传承人。 坚守初心 苦研技艺 在传承传统技艺的同时，李宁还基于现实需求不断改善西黄丸制备工艺，提升产品质量。2012年，新版药 典规定西黄丸要检测胆红素的含量，她通过研究分析，在生产中采用等量递增的方法将药粉与细料套研， 混合均匀，保证了关键成分胆红素含量的稳定性。 一是套研，将制作西黄丸的各类药粉倒入容器以一定比例均匀混合后，通过精准晃动，反复过锣，保证药 粉均一性。 二是起母子、培面，因为西黄丸成药个头小，故"母子"的规格较其他丸剂都要小很多。李宁可精准掌握加 入的药粉量与黏合剂用量、精准协调加入药粉与黏合剂的时机，确保药粉与黏合剂混合后，形 ...

证券代码： 300158 证券简称：振东制药 山西振东制药股份有限公司投资者关系活动记录表 编号：2025-001 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | ☑业绩说明会 □媒体采访 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 年 月 日(周二)下午 2025 5 20 14:00-17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采用 | | | 网络远程的方式召开业绩说明会 | | | 1、董事长李昆 | | 上市公司接待人 | 2、董事会秘书王哲宇 | | 员姓名 | 3、财务总监詹建勇 | | | 4、独立董事靳黎娜 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： 1、2024 年公司新增的独一味颗粒、灯盏花素分散片、注射 | | | 用头孢硫脒三个集采中选品种，同时实现舒血宁注射液的扩围接 | ...

Core Insights - Beijing Tongrentang Group, a leading enterprise in traditional Chinese medicine, integrates party building with production and operation to enhance economic and social benefits [1][2] - The State Council's opinion emphasizes improving the quality of traditional Chinese medicine, supported by technological innovation and institutional reforms, aiming for a high-quality development framework in the industry [1] - In response to market competition, the company focuses on quality improvement and efficiency enhancement, implementing cost-saving measures and promoting technological innovation [1][3] Group 1 - In the first quarter of 2025, Beijing Tongrentang Group actively participated in the Wuzhen Health Conference to expand national and cross-regional cooperation [2] - The "Party Building Leading Old Brand Industry Innovation Alliance" has expanded its membership, enhancing collaboration and innovation among various sectors [3] - The company has identified three core products for promotion in 2025: Angong Niuhuang Wan, Tongren Niuhuang Qingxin Wan, and Tongren Wujin Baifeng Wan, aiming for steady sales growth [3] Group 2 - Tongrentang Technology Company focuses on core business and industry chain collaboration, emphasizing research innovation and lean production [4] - The "Flag Planting Action" initiated in 2023 aims to deepen market penetration and enhance brand recognition through targeted services and cultural integration [5] - The company has established partnerships with major chain pharmacies to set ambitious quarterly and annual goals for market development [6] Group 3 - As of March 2025, Tongrentang Commercial Company operates 1,270 stores and 738 medical institutions across 190 cities, providing professional pharmaceutical services [7] - The company aims to enhance product variety and operational capabilities while promoting the sale of major products [7] - Future strategies include a "one-stop" health management solution through an integrated online and offline approach [7]

同仁堂科技公司大品种 同仁堂科技公司六味地黄丸系列 2025年一季度，北京同仁堂科技发展股份有限公司（以下简称"同仁堂科技公司"），以市场需求为导向，深化品种与渠道建设，不断激发营销动能。 一季度，"聚焦"是关键词，企业针对市场需求，将推广资源向大品种、中线品种、御药300年、阿胶、儿药等品种倾斜，形成结构清晰的品种群。 深入社区开展产品知识教育 在面向客群的产品宣贯上，企业聚焦于对年轻受众的穿透。2025年年初，借助亚冬会引发的冰雪运动热，同仁堂科技公司策划的"京牛冰雪季"让冰城哈尔滨 涌动"袪火养生潮"还未消散。4月，同仁堂科技公司又在"京东超级品牌日"推出了"北京同仁堂超好丸"活动，"对当下年轻人既追求养生又抗拒说教的心理,我 们尝试了与常规科普不一样的思路。"同仁堂科技公司相关负责人表示。 同 同仁堂科技公司京制牛黄解毒片 仁堂科技公司西黄丸 以核心品种西黄丸、京制牛黄解毒片和六味地黄丸系列为例，企业优化品种价格体系，细化品种政策和运营策略，铺市工作取得了突破性进展——西黄丸、 京制牛黄解毒片、六味地黄丸系系列均已覆盖全国30个省份以上。 同仁堂科技公司营销工作也继续聚焦于"插旗行动"。一季度，"插旗 ...

Company Performance - Guangyuyuan achieved an operating income of 1.22 billion yuan and a net profit attributable to shareholders of 74.45 million yuan for the year 2024 [1] - In Q1 2025, the company reported an operating income of 417 million yuan, a year-on-year increase of 21.48%, and a net profit of 63.58 million yuan, up 53.94% year-on-year [1] Industry Overview - The pharmaceutical manufacturing industry in China has shown signs of transformation driven by policy changes and market demand, with total operating income for 2024 at 25,298.5 billion yuan, remaining stable compared to 2023 [2] - The total profit for the pharmaceutical manufacturing industry in 2024 was 342.07 billion yuan, reflecting a year-on-year decline of 1.1%, although the rate of decline has slowed [2] - The traditional Chinese medicine sector is recovering growth due to government support and external factors such as an aging population and increased health demands [2] R&D and Innovation - Guangyuyuan has a history of 484 years and is recognized as a "Chinese Time-honored Brand," with key products included in national and provincial intangible cultural heritage lists [3] - The company increased its R&D expenditure to 38.59 million yuan in 2024, a 22.98% increase from the previous year, focusing on key products to enhance competitiveness [3] - Guangyuyuan is committed to a dual-driven development model of inheritance and innovation, collaborating with research institutions to create profitable research outcomes [3] Marketing Strategy - There is a growing demand for traditional Chinese medicine for health maintenance, with Guangyuyuan's products targeting specific consumer groups, indicating potential growth in the outpatient market [4] - The company has deepened strategic partnerships with top-tier chains and expanded its marketing channels, leading to significant growth in sales revenue [4] - Guangyuyuan has established a digital economy division to enhance online sales channels, adapting to new consumer trends and creating a strong competitive advantage [4]